# Lancovutide (Moli1901) Inhalation Solution Study in Adolescents and Adults With Cystic Fibrosis

> **NCT00671736** · PHASE2 · COMPLETED · sponsor: **AOP Orphan Pharmaceuticals AG** · enrollment: 160 (estimated)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** Moli1901
- **DRUG:** Moli1901 placebo

## Key facts

- **NCT ID:** NCT00671736
- **Lead sponsor:** AOP Orphan Pharmaceuticals AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2009-07
- **Final completion:** 2009-07
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2009-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00671736

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00671736, "Lancovutide (Moli1901) Inhalation Solution Study in Adolescents and Adults With Cystic Fibrosis". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT00671736. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*